Corrective advertisements about the use of aspirin for prevention of first heart attacks will not be required by FDA, Commissioner Young told a March 9 press briefing. "We thought about [whether it] would be helpful to put out [a corrective] ad saying 'Don't do it,' and we decided not to because we felt that saying 'Don't do it' would heighten the 'Do it' portion of the message," Young said.
You may also be interested in...
If President Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsberg, Affordable Care Act coverage could disappear. See what Kyle Sampson, a partner with the Washington, DC law firm King & Spalding said about it here.
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.